drugset / Trial / NCT01561755

A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy

NCT01561755

Phase 4 Terminated 12 enrolled David M. Simpson CSL Behring · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an effective treatment for HIV associated myelopathy.

Timeline

Start
2012-02
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 2 g/kg Intravenous